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ABSTRACT
BACKGROUND: Limited data are available on the prognosis of progressive mitral stenosis 
(MS). We evaluated the factors associated with adverse events in patients with progressive MS.
METHODS: We retrospectively analyzed 259 consecutive patients with pure progressive MS 
with a mitral valve area (MVA) between 1.5 and 2.0 cm2. The primary outcome measures were 
a composite endpoint of cardiac death, heart failure hospitalization, mitral valve surgery or 
percutaneous mitral valvuloplasty, and ischemic stroke.
RESULTS: The mean patient age was 62 ± 12 years, and the mean MVA was 1.71 ± 0.15 cm2. 
Over a median follow-up duration of 52 months, a total of 41 patients (18.3%) experienced 
the composite endpoint. In multivariable Cox regression analysis, prior stroke (hazard ratio 
[HR], 4.54; 95% confidence interval [CI], 2.16–9.54; p < 0.001) and left atrial volume index 
(LAVI) of > 50 mL/m2 (HR, 4.45; 95% CI, 1.31–15.31; p = 0.017) were identified as independent 
predictors of the composite endpoint, even after adjusting for age and sex. Patients with a 
LAVI ≤ 50 mL/m2 demonstrated favorable event-free survival compared with those with a LAVI 
> 50 mL/m2 in either the overall population (p < 0.001) or asymptomatic patients (p = 0.002). 
Atrial fibrillation (AF), left ventricular mass index (LVMI), MVA, and mean diastolic pressure 
were factors independently associated with LAVI (all p < 0.05).
CONCLUSIONS: A deleterious impact of a high LAVI on outcome was observed in patients 
with progressive MS. The LAVI was mainly influenced by the presence of AF, the severity of 
MS, and LVMI in this population.
Keywords: Mitral stenosis; Left atrial volume; Prognosis
INTRODUCTION
Mitral stenosis (MS) is the narrowing of the mitral valve orifice. It is almost always rheumatic 
in origin, although the incidence of degenerative MS due to heavy calcification of the mitral 
valve apparatus is increasing in elderly populations.1) The mitral valve orifice is slowly 
narrowed by progressive fibrosis, calcification of the valve leaflets, and fusion of the cusps 
and subvalvular apparatus.2) Severe or significant MS is diagnosed when the planimetered 
mitral valve area (MVA) is 1.5 cm2 or less. MS with an MVA of >1.5 cm2 is categorized as 




Received: Nov 29, 2018
Revised: Jan 25, 2019
Accepted: Feb 14, 2019
Address for Correspondence: 
Hyuk-Jae Chang, MD, PhD
Division of Cardiology, Severance 
Cardiovascular Hospital, Yonsei University 
College of Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea.
E-mail: hjchang@yuhs.ac
Copyright © 2019 Korean Society of 
Echocardiography
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 














The authors have no financial conflicts of 
interest.
In-Jeong Cho , MD1, Hyeonju Jeong , MD2, Jah-Yeon Choi , MD, PhD3,  
Sang-Eun Lee , MD, PhD3, and Hyuk-Jae Chang  , MD, PhD3
1 Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha 
Womans University College of Medicine, Seoul, Korea
2Division of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang, Korea
3Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
Prognostic Implications of the Left 
Atrial Volume Index in Patients with 
Progressive Mitral Stenosis
progressive MS and is generally considered clinically insignificant.1)3) The indication for 
intervention is limited to patients with clinically significant MS with an MVA ≤1.5 cm2, and 
there are limited treatment options for progressive MS. Percutaneous mitral valvuloplasty 
(PMV) may be considered in symptomatic patients with an MVA >1.5 cm2 if symptoms 
cannot be explained by another cause or if there is evidence of hemodynamically significant 
MS during exercise.1)3) Regular echocardiographic follow-up at 3–5-year intervals is the 
only current recommendation for patients with progressive MS,1) and strategies to identify 
patients at a high risk of adverse cardiac events have not been established. Therefore, we 
aimed to identify clinical and echocardiographic predictors for adverse events in patients 
with progressive MS of an MVA between 1.5 and 2.0 cm2 and to establish associated factors.
METHODS
Patients
We retrospectively reviewed patients diagnosed with rheumatic progressive MS (MVA 
between 1.5 and 2.0 cm2) who underwent echocardiography at a tertiary referral hospital 
for valvular heart disease from January 2004 to December 2016. The exclusion criteria were 
as follows: > 1+ mitral valve regurgitation, > 1+ aortic valve regurgitation and/or a condition 
more severe than mild aortic stenosis, congenital or myopathic lesions that could affect 
the left ventricular (LV) function or pulmonary artery pressure, and a history of PMV. 
Therefore, the sample for analysis included 225 patients with rheumatic pure progressive 
MS. Hypertension was defined as a systolic blood pressure (BP) of ≥ 140 mmHg and/
or a diastolic BP of ≥ 90 mmHg or use of antihypertensive agents. Diabetes mellitus was 
defined as receiving anti-diabetic treatment or a fasting plasma glucose level of ≥ 126 mg/
dL. Dyslipidemia was defined as the use of cholesterol-lowering medication or a serum 
total cholesterol level of ≥ 200 mg/dL. CHA2DS2-VASc score was calculated on the basis of 
the presence of congestive heart failure, hypertension, age, diabetes mellitus, prior stroke 
or transient ischemic attack, vascular disease, and female sex, as previously described by 
Lip et al.4) Vascular disease prior to myocardial infarction and peripheral artery disease was 
included. Kidney function was ascertained by the estimated glomerular filtration rate (GFR), 
calculated using the formula developed and validated in the Modification of Diet in Renal 
Disease(MDRD) study as follows5): GFR (mL/min/1.73 m2) = 186.3 × (serum creatinine [mg/
dL]-1.154 × age-0.203 (× 0.742, if female). This study was approved by the Institutional Review 
Board of Yonsei University, Severance Hospital, Seoul, Republic of Korea.
Echocardiographic examination
The LV end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), septal 
thickness, and LV posterior wall thickness were measured at end-diastole from the 
parasternal short-axis view. The LV ejection fraction (LVEF) was calculated using the LVEDD 
and LVESD. The LV mass was calculated using the formula set forth by the American Society 
of Echocardiography,6) and the LV mass index (LVMI) was the indexed LV mass for the body 
surface area (BSA). The left atrial (LA) volume was calculated from the parasternal long-
axis view and apical four-chamber view using the prolate ellipse method.7) The LA volume 
index (LAVI) was the indexed LA volume for the BSA. The systolic pulmonary artery pressure 
(SPAP) was calculated as follows: 4 × (maximum velocity of the tricuspid regurgitant jet)2 
+ right atrial pressure. The right atrial pressure was estimated by measuring the inferior 
vena cava diameter and its response to inspiration.8) The mean diastolic pressure gradient 
(MDPG) was measured from a continuous wave Doppler signal across the mitral valve by 
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tracing its envelope. The MVA was assessed using two-dimensional planimetry. The MVA by 
pressure half time (PHT) was calculated using the formula 220/PHT.9) The net atrioventricular 
compliance (Cn) was determined using the following equation: Cn (mL/mmHg) = 1270 
× (planimetric MVA/E-wave downslope).10)11) The echocardiographic measurements were 
averaged for three beats in patients with sinus rhythm and for five beats in those with atrial 
fibrillation (AF). Severe tricuspid regurgitation (TR) was defined in accordance with the 
American Society of Echocardiography guidelines.12)
Study endpoint
The patients were followed up across a median of 52 months (interquartile range, 17–95 
months) for a composite endpoint that included cardiac deaths, inpatient admissions for 
heart failure, mitral valve replacement (MVR), PMV, and ischemic stroke. The occurrence of 
any of the aforementioned clinical events that comprised the composite study endpoint was 
ascertained by a review of hospital records and by telephone interview, as necessary.
Statistical methods
The demographic characteristics were reported as percentages or mean ± SD. The patient 
groups were compared using chi-square statistics for categorical variables and Student's 
t-test for continuous variables. Receiver-operating characteristic (ROC) curves were plotted 
to determine the sensitivity and specificity of the different echocardiographic variables in 
predicting all events and to determine the cut-off value. The ROC curves were compared 
using a procedure previously described by DeLong et al.13) Univariable and multivariable Cox 
proportional hazards regression models reporting the hazard ratios (HRs) and 95% confidence 
intervals (95% CIs) were employed to determine potentially useful variables for predicting 
the event-free survival rate following echocardiography. Variables that displayed statistical 
significance in the univariable analysis were entered in the multivariable Cox model. Kaplan-
Meier survival curves were used to plot all clinical events according to the time-to-first event. 
In an effort to determine potential independent associations between the clinical factors and 
LAVI, linear relationships were checked using univariable linear regression analysis. Variables 
displaying statistical significance in the univariable analysis were entered into a multivariable 
linear regression model. A p-value < 0.05 was considered statistically significant.
RESULTS
Baseline clinical characteristics
The baseline characteristics of the study population are shown in Table 1. Mean patient age 
was 62 ± 12 years; approximately 75.6% of them were women, and 27.1% were symptomatic. 
The mean MVA via planimetry was 1.74 ± 0.14 cm2. The patients were classified into two 
groups according to the occurrence of the primary endpoint. Patients who experienced the 
study endpoint had a higher incidence of prior stroke (24.4% vs. 7.1%, p = 0.001).
No significant differences in demographic characteristics, including age, sex, BSA, 
hypertension, diabetes, dyslipidemia, current smoking, prior vascular disease, symptomatic 
status, BP, and medications, were found between the groups. The prescription rate of renin-
angiotensin system blockers was higher in patients with events (p = 0.020). Eighty patients 
(35.6%) used anticoagulants. The only anticoagulant used was a vitamin K antagonist; none 
of the patients received direct oral anticoagulants. The LAVI was higher in patients with 
events than in those without events (66.1 ± 25.5 mL/m2 vs. 51.8 ± 22.9 mL/m2, p < 0.001), 
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whereas the LVEDD, LVESD, LVEF, LVMI, MVA, MDPG, Cn, SPAP, and prevalence of severe 
TR were not significantly different between groups (all p ≥ 0.05).
Predictors for clinical outcomes
Over the course of the study period, a total of 41 patients (18.3%) experienced the composite 
endpoint. Specifically, three patients (1.3%) experienced death from cardiac causes; eight 
(3.6%) inpatient admissions for heart failure; 12 (5.3%) MVRs; two (0.9%) PMVs; and 16 
(7.1%) strokes.
The results of the ROC curve analysis for the prediction of the composite endpoint are shown 
in Figure 1. The area under curve (AUC) was 0.701 (95% CI, 0.636–0.760) for the LAVI, 0.522 
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Table 1. Baseline characteristics
Variables Overall (N = 225) Without events (n = 184) With events (n = 41) p-value
Demographics
Age (years) 62 ± 12 61 ± 12 64 ± 11 0.233
Female sex 170 (75.6) 138 (75.0) 32 (78.0) 0.681
AF 93 (41.3) 72 (39.1) 21 (51.2) 0.155
Body surface area (m2) 1.62 ± 0.17 1.62 ± 0.17 1.62 ± 0.18 0.945
Hypertension 111 (49.3) 88 (47.8) 23 (56.1) 0.338
Diabetes 42 (18.7) 32 (17.4) 10 (24.4) 0.298
Dyslipidemia 60 (26.7) 46 (25.0) 14 (34.1) 0.231
Current smoking 7 (3.1) 7 (3.8) 0 (0) 0.355
Prior stroke 23 (10.2) 13 (7.1) 10 (24.4) 0.001
Prior vascular disease 7 (3.1) 5 (2.7) 2 (4.9) 0.471
Symptomatic 61 (27.1) 48 (26.1) 13 (31.7) 0.464
Systolic BP (mmHg) 122.1 ± 21.7 120.7 ± 21.7 128.4 ± 20.9 0.089
Diastolic BP (mmHg) 76.9 ± 14.8 76.4 ± 15.5 79.1 ± 11.3 0.378
CHA2DS2-VASc score 2.3 ± 1.5 2.2 ± 1.5 2.7 ± 1.6 0.048
CHA2DS2-VASc score ≥ 2 140 (62.2) 109 (59.2) 31 (75.6) 0.051
Medication
Anticoagulation 80 (35.6) 65 (35.3) 15 (36.6) 0.879
Antiplatelet agent 71 (31.6) 55 (29.9) 16 (39.0) 0.255
Calcium channel blocker 63 (28.0) 47 (25.5) 16 (39.0) 0.082
Beta blocker 49 (21.8) 38 (20.7) 11 (26.8) 0.386
Renin-angiotensin system blocker 70 (31.1) 51 (27.7) 19 (46.3) 0.020
Laboratory test
Hemoglobin (g/dL) 13.2 ± 1.8 13.0 ± 1.8 13.6 ± 1.5 0.074
GFR, mL/min/1.73 m2 74.8 ± 18.7 74.5 ± 19.5 75.7 ± 15.1 0.727
AST (IU/L) 23.6 ± 13.9 24.1 ± 14.9 21.8 ± 8.2 0.364
ALT (IU/L) 21.3 ± 13.4 21.8 ± 14.5 19.1 ± 6.8 0.251
Echocardiography
LVEDD (mm) 48.4 ± 4.5 48.3 ± 4.3 48.9 ± 5.2 0.473
LVESD (mm) 32.1 ± 4.2 32.0 ± 4.0 32.7 ± 4.8 0.340
LVEF (%) 65.3 ± 7.1 65.5 ± 6.8 64.7 ± 8.3 0.512
LVMI (g/m2) 98.2 ± 22.9 97.7 ± 23.0 100.6 ± 22.2 0.466
LAVI (mL/m2) 54.2 ± 24.0 51.8 ± 22.9 66.1 ± 25.5 < 0.001
MVA by planimetry (cm2) 1.74 ± 0.14 1.74 ± 0.14 1.73 ± 0.14 0.716
MVA by pressure half time (cm2) 1.83 ± 0.32 1.84 ± 0.31 1.80 ± 0.33 0.525
MDPG (mmHg) 3.6 ± 1.1 3.6 ± 1.1 3.4 ± 1.1 0.399
Cn (mL/mmHg) 7.4 ± 1.7 7.42 ± 1.73 7.35 ± 1.67 0.800
SPAP (mmHg) 29.6 ± 8.3 29.5 ± 8.4 30.0 ± 7.6 0.696
SPAP ≥ 50 mmHg 4 (1.8) 4 (2.2) 0 (0) 0.999
Severe TR 1 (0.4) 0 (0) 1 (2.4) 0.182
AF: atrial fibrillation, ALT: alkaline phosphatase, AST: aspartate aminotransferase, BP: blood pressure, Cn: net atrioventricular compliance, GFR: glomerular 
filtration rate, LAVI: left atrial volume index, LVEDD: left ventricular end-diastolic diameter, LVEF: left ventricular ejection fraction, LVESD: left ventricular end-
systolic diameter, LVMI: left ventricular mass index, MDPG: mean diastolic pressure gradient, MVA: mitral valve area, SPAP: systolic pulmonary artery pressure, 
TR: tricuspid regurgitation.
Data are shown as number (%).
(95% CI, 0.454–0.590) for the LVEF, 0.538 (95% CI, 0.470–0.605) for the LVMI, 0.514 (95% CI, 
0.446–0.582) for the planimetered MVA, and 0.538 (95% CI, 0.470–0.605) for the MDPG. The 
differences between the AUC of the LAVI and those of other variables, including LVEF, LVMI, 
MVA, and MDPG, were all significant (all p < 0.05). The optimal cut-off value according to the 
ROC curves for the LAVI was 50 mL/m2 (sensitivity = 78.0%, specificity = 59.8%).
Table 2 shows the baseline characteristics and endpoints during follow-up in the subgroup 
of 93 patients with AF. Of the patients, 58 (62.4%) received anticoagulation and 35 (37.6%) 
did not. The prevalence of a CHA2DS2-VASc score ≥ 2 was higher in the patients who received 
anticoagulation than in those who did not receive anticoagulation (67.2% vs. 54.3%), although 
the difference was not statistically significant. The composite endpoint did not statistically 
differ between the groups, but the actual prevalence of stroke was higher in the patients who 
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Figure 1. Comparison of the ROC curves for the prediction of adverse events in patients with progressive mitral 
stenosis. Area under curve: LAVI = 0.701 (95% CI, 0.636–0.760), LVEF = 0.522 (95% CI, 0.454–0.590), LVMI = 
0.538 (95% CI, 0.470–0.605), MVA = 0.514 (95% CI, 0.446–0.582), and MDPG = 0.538 (95% CI, 0.470–0.605). CI: 
confidence interval, LAVI: left atrial volume index, LVEF: left ventricular ejection fraction, LVMI: left ventricular mass 
index, MDPG: mean diastolic pressure gradient, MVA: mitral valve area, ROC: receiver-operating characteristic.
Table 2. Characteristics of the subgroup patients with atrial fibrillation
Variables Anticoagulation CHA2DS2-VASc score ≥ 2
Yes (n = 58) No (n = 35) p-value No (n = 36) Yes (n = 57) p-value
Age (years) 65 ± 9 65 ± 9 0.697 65 ± 10 65 ± 9 0.986
Female sex 46 (79.3) 26 (74.3) 0.574 30 (83.3) 42 (73.7) 0.278
Prior stroke 9 (15.5) 2 (5.7) 0.198 4 (11.1) 7 (12.3) 0.999
Anticoagulation 58 (100) 0 (0) - 20 (55.6) 38 (66.7) 0.281
CHA2DS2-VASc score 2.4 ± 1.6 2.2 ± 1.6 0.111 0.8 ± 0.4 3.2 ± 1.3 < 0.001
CHA2DS2-VASc score ≥ 2 39 (67.2) 19 (54.3) 0.281 0 (0) 57 (100) -
Endpoint 12 (20.7) 9 (25.7) 0.535 5 (13.9) 16 (28.1) 0.111
Cardiac death 2 (3.4) 0 (0) 1 (2.8) 1 (1.8)
HF administration 2 (3.4) 2 (5.7) 1 (2.8) 3 (5.3)
MVR or PMV 4 (6.9) 3 (8.6) 2 (5.6) 5 (8.8)
Stroke 4 (6.9) 4 (11.4) 1 (2.8) 7 (12.3)
HF: heart failure, MVR: mitral valve replacement, PMV: percutaneous mitral valvuloplasty.
Data are shown as number (%).
did not receive anticoagulation (11.4% vs. 6.9%). When the AF patients were grouped according 
to the CHA2DS2-VASc score, 36 patients had CHA2DS2-VASc scores < 2 and 57 had CHA2DS2-
VASc scores ≥ 2. The patients with CHA2DS2-VASc scores ≥ 2 showed a higher stroke prevalence 
during follow-up, but this difference was not statistically significant (2.8% vs. 12.3%, p = 0.111).
Table 3 shows the results of the univariable Cox regression analysis for the prediction of 
the composite endpoint. Prior stroke (HR, 3.84; 95% CI, 1.87–7.92; p < 0.001) and a LAVI > 
50 mL/m2 (HR, 4.19; 95% CI, 2.05–8.57; p < 0.001) were the predictors for the composite 
endpoint. Table 4 describes the results of the multivariable Cox regression analysis for the 
prediction of the composite endpoint. In various multivariable models, prior stroke and a 
LAVI > 50 mL/m2 were the independent predictors of the composite endpoint (all p < 0.05), 
even after adjustment for variables.
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Table 3. Univariable Cox regression analysis for the prediction of the composite endpoints
Variables Hazard ratio 95% confidence interval p-value
Age, per 10 years 1.30 0.98–1.74 0.073
Female sex 1.17 0.56–2.45 0.679
AF 1.64 0.89–3.04 0.112
Hypertension 1.36 0.73–2.52 0.332
Diabetes 1.54 0.75–3.14 0.237
Prior stroke 3.84 1.87–7.92 < 0.001
CHA2DS2-VASc score ≥ 2 1.76 0.86–3.59 0.121
Anticoagulation 1.02 0.54–1.94 0.948
Renin-angiotensin system blocker 1.87 0.57–6.17 0.301
Symptomatic 1.57 0.81–3.04 0.182
LVEF ≤ 65% 1.07 0.58–1.98 0.828
LVMI > 115 g/m2 1.86 0.97–3.56 0.063
LAVI > 50 mL/m2 4.19 2.05–8.57 < 0.001
MVA by planimetry ≤ 1.75 cm2 1.03 0.56–1.91 0.916
MDPG > 3.5 mmHg 1.13 0.61–2.09 0.699
SPAP > 30 mmHg 1.12 0.60–2.07 0.723
Cn ≤ 7.2 mL/mmHg 1.24 0.67–2.29 0.495
AF: atrial fibrillation, Cn: net atrioventricular compliance, LAVI: left atrial volume index, LVEF: left ventricular 
ejection fraction, LVMI: left ventricular mass index, MDPG: mean diastolic pressure gradient, MVA: mitral valve 
area, SPAP: systolic pulmonary artery pressure.
Table 4. Multivariate Cox regression analysis for the prediction of the composite endpoints
Variables Hazard ratio 95% confidence interval p-value
Model 1
Age, per 10 years 1.26 0.94–1.69 0.123
Female 1.08 0.51–2.31 0.839
Prior stroke 4.54 2.16–9.54 < 0.001
LAVI > 50 mL/m2 4.45 1.31–15.13 0.017
Model 2
Age, per 10 years 1.24 0.91–1.68 0.174
Female 1.08 0.51–2.31 0.836
AF 1.17 0.61–2.27 0.637
Prior stroke 4.47 2.12–9.41 < 0.001
LAVI > 50 mL/m2 4.12 1.17–14.57 0.028
Model 3
Age, per 10 years 1.25 0.93–1.69 0.134
Female 1.08 0.51–2.29 0.850
CHA2DS2-VASc score ≥ 2 1.56 0.76–3.19 0.225
Prior stroke 4.36 2.07–9.22 < 0.001
LAVI > 50 mL/m2 4.25 1.25–14.50 0.021
AF: atrial fibrillation, LAVI: left atrial volume index.
Figure 2 shows the event-free survival rates for the composite endpoint stratified by the 
LAVI. Notably, patients with a LAVI ≤ 50 mL/m2 demonstrated a favorable event-free survival 
compared with those with a LAVI > 50 mL/m2 in the overall population (log-rank p < 0.001) 
and asymptomatic patients (log-rank p = 0.002). Figure 3 shows the Kaplan-Meier curve of 
event-free survival rates for each endpoint stratified by the LAVI in the overall population. 
The patients with a LAVI ≤ 50 mL/m2 demonstrated a favorable event-free survival compared 
with those with a LAVI > 50 mL/m2 regarding cardiac death, heart failure hospitalization, and 
MVR or PMV (all log-rank p < 0.05). There were fewer stroke events in the patients with a 
LAVI ≤ 50 mL/m2, although this was not significantly different (log-rank p = 0.140).
Determinants of the LAVI
Table 5 shows the results of the univariable and multivariable linear regression analyses for the 
factors associated with the LAVI in progressive MS. In the univariable analysis, age (beta = 0.215, 
p = 0.001), AF (beta = 0.428, p < 0.001), LVMI (beta = 0.223, p = 0.001), MVA by planimetry (beta 
= -0.199, p = 0.003), MDPG (beta = -0.199, p = 0.003), and Cn (beta = -0.155, p = 0.020) showed 
significant correlations with the LAVI. In the multivariable analysis, AF, LVMI, MVA, and MDPG 
were the factors independently associated to LAVI, even after adjusting for age and Cn.
DISCUSSION
The principal findings of the current study are as follows: 1) approximately 18.3% of patients 
with progressive MS experienced cardiovascular events during the median follow-up period 
of 55 months; 2) a LAVI >50 mL/m2 was a prognostic marker for adverse cardiac events; and 
3) LVMI, severity of MS, and presence of AF were independent determinants of the LAVI in 
progressive MS.
Therapeutic strategies for progressive MS
Progressive MS is usually considered benign, and specific therapies are not recommended, 
except for regular follow-ups at 3–5-year intervals.1) Notably, 18.3% of the studied population 
experienced adverse events during a median follow-up of 4 years. The number of MVRs 
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Patients at risk
LAVI ≤ 50 mL/m2 116 84 68 50 31
LAVI > 50 mL/m2 109 74 49 30 17
Patients at risk
LAVI ≤ 50 mL/m2 94 66 56 41 26
LAVI > 50 mL/m2 92 53 34 25 14
n = 225
Log-rank p < 0.001
n = 186
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Figure 2. Kaplan-Meier curve showing the event-free survival rate for the composite primary endpoint stratified by the LAVI. Overall population (A) and 
asymptomatic patients (B). LAVI: left atrial volume index.
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Patients at risk
LAVI ≤ 50 mL/m2 116 84 64 50 31
LAVI > 50 mL/m2 109 74 49 30 17
Patients at risk
LAVI ≤ 50 mL/m2 116 84 68 50 31
LAVI > 50 mL/m2 109 74 49 30 17
Patients at risk
LAVI ≤ 50 mL/m2 116 84 64 50 31
LAVI > 50 mL/m2 109 74 49 30 17
Patients at risk
LAVI ≤ 50 mL/m2 116 84 64 50 31
LAVI > 50 mL/m2 109 74 49 30 17
n = 225
Log-rank p = 0.032
n = 225
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Figure 3. Kaplan-Meier curve showing the event-free survival rate for the individual endpoints stratified by the LAVI in the overall population. Cardiac death 
(A), HF hospitalization (B), MVR or PMV (C), and ischemic stroke (D). HF: heart failure, LAVI: left atrial volume index, MVR: mitral valve replacement, PMV: 
percutaneous mitral valvuloplasty.
Table 5. Univariable and multivariable linear regression analyses for the factors associated with the left atrial 
volume index in progressive mitral stenosis
Variables Univariable Multivariable
beta p-value beta p-value
Age 0.215 0.001 0.076 0.232
Female sex 0.061 0.365 - -
AF 0.438 < 0.001 0.420 < 0.001
Hypertension 0.069 0.306 - -
Diabetes 0.016 0.817 - -
Prior stroke 0.025 0.714 - -
LVEF −0.063 0.351 - -
LVMI 0.223 0.001 0.267 < 0.001
MVA by planimetry −0.199 0.003 −0.152 0.011
MDPG 0.199 0.003 0.161 0.017
Cn −0.155 0.020 0.005 0.942
AF: atrial fibrillation, Cn: net atrioventricular compliance, LVEF: left ventricular ejection fraction, LVMI: left 
ventricular mass index, MDPG: mean diastolic pressure gradient, MVA: mitral valve area.
or PMVs that were performed, significantly increased 3 years from the first diagnosis of 
progressive MS. Therefore, our data suggest that follow-up at 3-year intervals might be an 
appropriate option for detecting the progression of disease in MS, considering the relatively 
high incidence of events during follow-up in progressive MS.
Surprisingly, the incidence of AF in our study was approximately 40% in all patients, and 
10% had a history of stroke at baseline, although progressive MS is usually considered 
clinically insignificant. AF in progressive MS is basically categorized as nonvalvular AF in the 
recent guidelines.14) However, specific data regarding anticoagulation strategies, including 
vitamin K antagonist or non-vitamin K antagonist oral anticoagulant administration and 
the prognostic role of the CHA2DS2-VASc score4) in targeting progressive MS with AF, are 
lacking. Additionally, the treatment options for progressive MS with a sinus rhythm have 
been investigated less. Adequate anticoagulation should be considered for AF patients 
with progressive MS, as our retrospective analysis showed that many of the patients with 
progressive MS who had high CHA2DS2-VASc scores did not receive anticoagulation and that 
> 12% eventually had a stroke during a median follow-up of 52 months. Therefore, adequate 
anticoagulation directed by the CHA2DS2-VASc score is essential for the treatment of 
progressive MS. Moreover, specific therapeutic strategies for progressive MS according to risk 
stratification need further investigation.
LAVI as a predictor for progressive MS
The LAVI is a prognostic marker for cardiovascular outcomes in the general population,15)16) as 
well as various heart diseases, such as heart failure,17) hypertrophic cardiomyopathy,18)19) and 
ischemic cardiomyopathy.20)21) In valvular heart disease, the LAVI was a prognostic marker for 
cardiovascular outcomes after mitral valve surgery22) and in medically treated patients with 
mitral regurgitation.23)
The ability of the LAVI to predict outcomes in patients with MS is less clear. Ancona et al.24) 
reported that LA volumes did not predict the AF incidence in patients with MS, although the 
increase in the upstream pressure usually leads to progressive enlargement of the LA in MS. We 
found that the LAVI may serve as a prognostic marker in progressive MS. This discrepancy might 
have resulted from the fact that our population was composed of patients with less severe MS 
and an MVA > 1.5 cm2; therefore, the influence of MS severity on the outcomes was attenuated, 
and the prognostic power of the LAVI was enhanced. The LAVI might also be applicable for each 
event, such as cardiac death, heart failure hospitalization, mitral valve intervention, and probably 
stroke, aside from the composite endpoint. Prior stroke was a powerful predictor for the future 
incidence of stroke but did not predict other cardiac events. In contrast, a high LAVI > 50 mL/m2 
was the only independent universal predictor for various cardiac events in progressive MS, which 
could be helpful for risk stratification in this population.
Determinants of the LAVI in progressive MS
We found that multiple factors are associated with the LAVI in progressive MS. The associated 
factors were AF, MVA, MDPG, and LVMI. It is not surprising that AF, MVA, and MDPG were 
factors associated with the LAVI, since AF induces LA electrical and mechanical remodeling,25) 
and the increase in the upstream pressure usually leads to progressive enlargement of the LA. 
Interestingly, we found that the LVMI was also closely associated with the LAVI in progressive 
MS. LV hypertrophy is associated with diastolic dysfunction and LV end-diastolic pressure 
increase, which can further exaggerate LA pressure increase and result in LA enlargement. We 
previously reported that LV diastolic function was an important factor of MDPG and LA reverse 
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remodeling in patients with severe MS.26) Similarly, LV hypertrophy and associated LV diastolic 
function might exaggerate LA enlargement and accelerate poor clinical outcomes. Therefore, 
LV hypertrophy and diastolic dysfunction can be a target of treatment for progressive MS, 
although the assessment of diastolic function in patients with MS is challenging.27)
Limitations
Several limitations need to be acknowledged. The current study findings were based on a 
retrospective analysis, which may infer some biases. Despite this, we carefully reviewed all 
medical records, along with echocardiographic images, in an effort to avoid any possible 
biases that may have arisen. Information regarding the duration of AF, which might have a 
significant impact on the outcomes, was unavailable. The reason for the low prevalence of 
anticoagulation in the AF patients is unclear as this study was a retrospective analysis and 
the patients were followed up and treated in accordance with the preference of the dedicated 
attending physician. TR can lead to hepatic congestion and fluctuation in the degree of 
anticoagulation, which can result in brain hemorrhage and ischemic stroke. However, severe 
TR was present in only one patient; therefore, its clinical significance cannot be determined 
in the present study and further investigation is warranted. The studied population consisted 
of patients at high risk of cardiovascular disease, with a high incidence of AF, hypertension, 
diabetes, and prior stroke. In addition, approximately 27% of patients were symptomatic, 
although they had clinically insignificant MS, and this might have caused a high incidence 
of the composite endpoint. As this study was performed retrospectively, it was difficult to 
clearly define etiology in all symptomatic patients. Exercise echocardiographic data were not 
available, and would be beneficial for risk stratification among patients with progressive MS 
symptoms in future studies.
Conclusions
A LAVI > 50 mL/m2 was a prognostic marker of adverse cardiac events in patients with 
progressive MS. The LAVI was mainly influenced by the presence of AF, the severity of MS, 
and LVMI in this population.
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